Thyroid Cancer

Anaplastic thyroid cancer is one of the most aggressive solid tumours.

That alone makes any plausible new mechanism worth attention.

For shikonin, the main thyroid-cancer signal is ferroptosis.

Why thyroid cancer is a logical target

Ferroptosis-vulnerable tumours tend to show high oxidative stress pressure and susceptibility to lipid peroxidation.

Anaplastic thyroid-cancer cells may fit that profile.

Shikonin appears able to exploit it.

Key evidence

In anaplastic thyroid-cancer cell lines, shikonin reduced cell growth and induced ferroptosis.

The mechanism was supported by lipid-peroxidation markers and reversal with ferroptosis inhibitors.

That is important because it distinguishes ferroptosis from generic oxidative injury claims.

Why this matters

This is the clearest cancer-type setting where ferroptosis is the central shikonin story rather than a side note.

That gives thyroid cancer a distinctive place in the wider evidence set.

Limits

• evidence is mainly one recent study

• no animal validation exists yet

• no data in papillary or follicular thyroid cancer

• no interaction data with lenvatinib, pembrolizumab, or other current ATC treatments

Bottom line

The thyroid-cancer evidence is promising but still very thin.

It is worth tracking because the mechanism is specific and the unmet need is high.

It is not yet a robust evidence area.

References

Shikonin inhibits the growth of anaplastic thyroid carcinoma cells via ferroptosis. Heliyon / ScienceDirect (2024).
https://www.sciencedirect.com/science/article/pii/S2405844024103222